Kornimate/medical-research-clean huggingface dataset:
the effect of osa on severity and prognosis of patients with igan

Conditions: Obstructive Sleep Apnea; IgA Nephropathy

Summary: this study aims to investigate the influence of obstructive sleep apnea hypopnea syndrome (osa) on the severity and prognosis of patients with iga nephropathy (igan), and to evaluate the therapeutic effect of continuous positive airway pressure (cpap) intervention in such patients. although the study is designed as an observational cohort study, where patients self-selected whether to receive treatment rather than being assigned, there is still an intervention project, cpap, present in the observational cohort. through a cohort study design, scientific evidences are expected for clinical decision-making and optimize treatment strategies for patients with osa and igan.


Eligibility criteria:
inclusion criteria: * diagnostic criteria: iga nephropathy is diagnosed based on the pathological results of renal biopsy and/or clinical manifestations (such as hematuria, proteinuria, abnormal renal function, etc.), in accordance with the internationally recognized diagnostic criteria for iga nephropathy. obstructive sleep apnea-hypopnea syndrome (osahs) is confirmed through overnight polysomnography (psg) with an apnea-hypopnea index (ahi) of ≥5 events per hour, primarily consisting of obstructive events. * age and gender: participants must be ≥18 years old, with no gender restrictions (as both osahs and iga nephropathy do not show significant gender predisposition). * informed consent: participants are required to voluntarily sign a written informed consent form, acknowledging and agreeing to participate in the study, including all its contents and potential risks. exclusion criteria: * other sleep-related breathing disorders: participants with mixed sleep apnea, central sleep apnea, or severe snoring with an ahi index of \<5 events per hour will be excluded to ensure that the study population is limited to patients with osahs. * severe internal medical conditions: patients with severe cardiopulmonary dysfunction, malignancy, severe liver disease, mental disorders, or other severe internal medical conditions that may significantly affect sleep or the progression of kidney disease will be excluded. * recent surgery or medication: individuals who have undergone surgery within the past 3 months that may affect sleep or kidney function, or who are currently using medications that may significantly interfere with sleep or the assessment of kidney disease (such as corticosteroids, immunosuppressants, novel antipsychotics, etc.) will be excluded. * pregnant women. * inability to cooperate with the study: patients who are unable to complete the study procedures (including polysomnography, follow-up, etc.) due to cognitive impairment, language communication difficulties, remote residence, or other reasons will be excluded.
effective study of arni on ventricular arrhythmia in hfref patients with icd or crt-d (rhythm)

Conditions: Heart Failure

Summary: the purpose of this study was to generate effectiveness data of angiotensin receptor neprilysin inhibitor (arni), in the chinese heart failure with reduced ejection fraction (hfref) patients with implantable cardioverted defibrillator (icd) or cardiac resynchronization therapy-defibrillator (crt-d).

the rationale of this study was to compare the effect of angiotensin-converting enzyme inhibitor (acei) / angiotensin receptor blockers (arb) with the effect of arni on ventricular arrhythmia (va) events for hfref patients with icd or crt-d, thus a multicenter, interventional, open-label, and prospective single-arm study was considered. acei/arb was given to the patient for 6 months. after 6 months, patients using acei needed to undergo a 36-hr washout period (36-hr washout period was not needed for patients using arb at month 6). patients then received arni (sponsored by novartis only for this study).

Eligibility criteria:
key inclusion criteria: 1. male or female patients ≥18 and ≤80 years of age 2. implanted with an icd or crt-d within 2 weeks 3. nyha functional class ii - iv 4. lvef ≤40% (measured by echocardiography) 5. signed informed consent must be obtained prior to participation in the study. key exclusion criteria 1. history of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes. 2. patient received target dose (≥200 mg/d) of arni for 2 weeks continuously within the 6-week period prior to study enrollment. 3. participation in other clinical studies 3 months prior to participating study. 4. advanced cancer or other significant comorbidities with life expectancy of \<1 year. 5. previous history of angioedema associated with acei/arb treatment, hereditary or idiopathic angioedema. 6. patients with renal artery stenosis history. 7. current stage d hf patients requiring vasoactive drugs. 8. symptomatic hypotension \< 100/60 mmhg at visit 1 (screening) or symptomatic hypotension \< 90/60 mmhg in anti-hypertension drug treatment at visit 1 (screening). 9. serum potassium \>5.4 mmol/l at visit 1 (screening). 10. estimated glomerular filtration rate (egfr) \< 30 ml/min/1.73m2 as measured at visit 1 (screening). 11. pregnant or nursing (lactating) women. 12. other exclusion depend on investigator's discretion.

Keywords: lcz696 sacubitril/valsartan heart failure heart failure with reduced ejection fraction hfref ventricular arrhythmias implanted device healthcare resource utilization
efficacy and safety of levocetirizine versus loratadine for the treatment of perennial allergic rhinitis

Conditions: Rhinitis; Allergic; Perennial

Summary: efficacy and safety of levocetirizine versus loratadine for the treatment of perennial allergic rhinitis.


Eligibility criteria:
inclusion criteria: * male ore female, 16 to 60 years old (inclusive) * two-year history of allergic rhinitis due to house dust mite exclusion criteria: * an ear, nose or throat (ent) infection * asthma requiring daily drug therapy other than ß2 inhaled agonists taken prn * atopic dermatitis or urticaria requiring an antihistamine or corticosteroid treatment * an associated ent disease * use of decongestants * nasal or ocular topical treatment * desensitivation

Keywords: levocetirizine dihydrochloride xyzal tablets
effect of hypericum perforatum oil on ecchymosis and pain

Conditions: Pain; Ecchymosis

Summary: low molecular weight heparin is a drug with anticoagulant and antithrombotic effects. this drug is frequently administered subcutaneously to patients by nurses. complications such as pain, ecchymosis and hematoma may commonly occur at the injection site. this study investigated the effect of hypericum perforatum oil in preventing pain and ecchymosis after subcutaneous injection low molecular weight heparin. this quasi-experimental and single blinded study was conducted with 160 patients in a coronary intensive care unit. the researcher nurse applied 5-6 drops of hypericum perforatum oil to one arm of the patients 2 hours before the injection. the other arm of the patient was considered as the control arm. a total of 320 injections were administered. the evaluation of the injection sites was performed by two other researchers at 48th hours. the data were analyzed using wilcoxon and mcnemar test.


Eligibility criteria:
inclusion criteria: * over 18 years of age * normal platelet value, * normal international normalised ratio (inr) and prothrombin time (ptz) values, * no infection, scar tissue or incision in the lateral upper arm exclusion criteria: * pregnancy * administration of haemodialysis

Keywords: hypericum perforatum oil low molecular weight heparin subcutaneous injection ecchymosis pain
safety and efficacy of remote ischemic conditioning in patients with spontaneous intracerebral hemorrhage

Conditions: Intracranial Hemorrhages

Summary: the purpose of this study is to determine whether treatment with remote ischemic conditioning is of sufficient promise to improve outcome before conducting a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.

intracerebral hemorrhage is a devastating disease with a high rate of severe disability and death, while no specific treatment has been proven to improve functional outcome. as a result, new approaches need to be developed to treat intracerebral hemorrhage. animal and human trials showed treatment with remote ischemic conditioning was safe for intracerebral hemorrhage. and repetitive remote ischemic conditioning has been shown to improve sensorimotor and neuropathological outcomes following experimental hemorrhagic stroke. therefore, we hypothesize that repetitive remote ischemic conditioning could improve functional outcome in patients with intracerebral hemorrhage. we design this prospective, multicenter, randomized controlled double-blind trial to determine whether treatment with remote ischemic conditioning is of sufficient promise to improve outcome before conducting a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. supratentorial intracerebral hemorrhage confirmed by brain ct scan 3. functional independence prior to ich, defined as pre-ich mrs ≤ 1 4. nihss score ≥ 4 and gcs ≥ 6 upon presentation 5. able to commence ric treatment within 12 hours of stroke onset 6. signed and dated informed consent is obtained. exclusion criteria: 1. definite evidence of secondary ich, such as structural abnormality, brain tumor, thrombolytic drug, and other causes 2. a very high likelihood that the patient will die within the next 24 hours on the basis of clinical and/or radiological criteria 3. already booked for surgical treatment 4. life expectancy of less than 90 days due to comorbid conditions 5. severe hematologic disease 6. concurrent use of anticoagulation drugs including warfarin, dabigatran, rivaroxaban. 7. concurrent use of glibenclamide or nicorandil 8. any soft tissue, orthopedic, or vascular injury, wounds or fractures in healthy upper limb which may pose a contraindication for application of ric 9. severe hepatic and renal dysfunction 10. platelet count \<100×10\^9/l 11. coagulopathy defined as inr,aptt,and pt beyond the upper limit of normal range 12. known pregnancy, or positive pregnancy test, or breastfeeding 13. patients being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial 14. a high likelihood that the patient will not adhere to the study treatment and follow up regimen 15. patients unsuitable for enrollment in the clinical trial according to investigators decision making.

Keywords: intracranial hemorrhages remote ischemic conditioning
observational study on the occurrence of hepatosplenic t-cell lymphoma in patients of netherlands

Conditions: Hepatosplenic T-cell Lymphoma

Summary: the purpose of this study is to examine reports of the cancer called hepatosplenic t-cell lymphoma (hstcl) in the dutch national database of pathology (pathologisch-anatomisch landelijk geautomatiseerd archief or palga) during the years 1995 to 2008.

this is a observational, retrospective (a study in which the participants are identified and then followed backward in time, for the outcome of the study) study. in this study review of all reports of possible cases of hepatosplenic t-cell lymphoma (hstcl) that were identified within the palga database of pathology results for the netherlands from 1995 to 2008. all patients whose information is contained within the palga database were prescribed treatments by a physician on the basis of usual clinical practice or may have received other treatments, including experimental drugs, while participating in an interventional clinical study. the identified data on each of the patients with reports of hstcl will be collected from the pathologist(s) who prepared the report and from the physician(s) who treated the patient at the time of diagnosis.

Eligibility criteria:
inclusion criteria: - patients diagnosed with hstcl in the dutch national database of pathology (pathologisch-anatomisch landelijk geautomatiseerd archief) database during the years 1995 to 2008 exclusion criteria: - patients who are not diagnosed with hstcl

Keywords: hepatosplenic t-cell lymphoma remicade infliximab dutch national database of pathology palga autoimmune disease non-hodgkin lymphoma
a multidomain approach to preventing dementia in african americans: cognitive prescriptions

Conditions: Cognitive Change; Health Behavior; Health Literacy

Summary: the goal of this r21 study is to explore the feasibility and preliminary efficacy of individualized cognitive prescriptions (cogrxs) in improving engagement in healthy behaviors and other outcomes in middle-aged aas and to gain feedback on future implementation of the program.

a pre-post experimental design will be used, in which 150 aa participants aged 50-65 will complete a baseline assessment of cognitive testing and data-driven assessment of deficiencies across five cogrx domains (physical activity, cognitive activity, diet, sleep, social activity). participants will be randomized to either: psychoeducation + cogrx, psychoeducation only, or no contact control. the psychoeducation and cogrx groups will receive general psychoeducation on dementia prevalence, prognosis, and risk factors, while the cogrx group will also receive personalized information on their risk factor profile and develop a tailored 3-month intervention plan, which will consist of simple evidence-based strategies to implement at home. motivational reminders as well as adherence and self-efficacy questions will be administered via text-messaging over the 3-months. participants will return for 3-month and 6-month follow-ups. specific aim 1 (proximal outcomes) is to determine whether the cogrx condition is superior to psychoeducation alone in improving engagement in healthy lifestyle behaviors. specific aim 2 (distal outcomes) is to compare the three conditions on a brief battery of cognitive and psychological measures. the exploratory aim is to gather feedback for future implementation of this program, including cultural considerations, barriers and facilitators to engagement, and likelihood of continuing the program.

Eligibility criteria:
inclusions: * must be african american * must be age 50 to 65 * must have a working cell phone with unlimited texting * must be ambulatory exclusions: * no neurological (including dementia diagnosis) or severe psychiatric (e.g., schizophrenia or bipolar disorder) disorders * no insomnia * telephone interview for cognitive status (tics) score ≤20
effectiveness of periodontitis treatment on the metabolic activity of symptomatic carotid atherosclerotic plaque responsible for ischemic stroke

Conditions: Severe Periodontitis; Ischemic Stroke

Summary: cardiovascular disease is the world's leading cause of death. atherothrombosis is a common cause of ischemic stroke. a strong epidemiological link has been established between periodontitis and the risk of stroke. it shares common risk factors with atherothrombosis, and its severe form is associated with low-grade systemic inflammation and daily low-intensity bacteremia. atherothrombosis is a frequent cause of ischemic stroke. periodontal bacteria have been found within atheromatous plaques, correlated with a greater risk of rupture. thus, periodontitis could be a modifiable risk factor for atherothrombosis and future vascular events: its early diagnosis and treatment could have a major impact on cardiovascular prevention. hypothesis: in patients with periodontitis who have had an ischemic stroke, periodontal treatment may reduce atherosclerotic plaque activity.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * minor ischemic stroke of the anterior circulation (nihss ≤ 5) of atherothrombotic origin according to the toast scale \<30 days * atheroma plaque of the ipsilateral carotid bulb \>30% not eligible for intervention (endarterectomy or angioplasty-stenting) * severe periodontitis (stage 3 or 4) * signed informed consent * affiliation to a social security scheme exclusion criteria: * \< 6 teeth * without independent oral hygiene * contraindications to pet scan * known allergy to fluoro-deoxyglucose and its excipient * immunosuppressive treatment * uncontrolled diabetes * high risk of infective endocarditis * organ transplant pending * progressive infectious diseases * active smoking not stopped * patient deprived of liberty by judicial or administrative decision * patient under legal protection (guardianship, curatorship) * participation in another interventional research involving humans or being in the exclusion period following previous research involving humans * pregnant or breastfeeding woman patient under ame (state medical aid)

Keywords: pet scan severe periodontitis ischemic stroke
project legacy impact evaluation study

Conditions: Pregnancy Prevention; Sexual Behavior; Contraception Behavior; Sexually Transmitted Diseases

Summary: this study will design and rigorously evaluate the efficacy of project legacy, a five week positive youth development intervention to decrease sexual risk for unintended pregnancies and stis among youth experiencing homelessness or at risk of homelessness aged 14-19. this randomized control trial will compare project legacy to a usual services control.

the study uses a multi-site randomized group trial (rgt) cohort design to evaluate the project legacy intervention curriculum for reducing sexual risk behaviors among homeless youth age 14-19. chla project staff will work with 6 homeless youth serving sites in southern california (los angeles, san diego) to recruit 600 youth. randomization to the intervention or control condition will occur at the group level and will be stratified by site. field staff will survey all eligible homeless youth who provide consent to participate in the study at baseline (before randomization and implementation) and at 3 and 9 months post intervention (5-5.5 and 11-11.5 months post-baseline). the program group will receive an additional intervention-based survey immediately upon completion of the program. youth in the control condition will receive the normal standard of care provided at the recruitment sites. services available as standard of care at the recruitment sites include: medical care; mental health services; substance abuse services; educational, career, and vocational services. intervention participants will not be excluded from receiving these services as well. surveys will capture mental and physical health care service utilization and services to reduce substance use across both groups. the study team will monitor hiv and pregnancy prevention programming and other similar goal-planning/decision-making interventions offered to homeless youth in the study areas during the program implementation and follow-up period via interviews with site staff. the study team will include selected program exposure items on the follow up surveys to assess youth's self-reported exposure to similar goal-planning/decision-making and sexual health (pregnancy prevention and sti/hiv) education.

Eligibility criteria:
inclusion criteria: * served or identified on outreach by one of our partner homeless youth serving agencies in los angeles or san diego * 14-19 years of age * english-language speaker (able to complete consent and survey in english) * not currently pregnant * no immediate travel plans (are planning on being in the area for the length of the intervention - 8 weeks). exclusion criteria: * outside of age range * currently pregnant * not planning to be in the area for the length of the intervention * previously enrolled in the study

Keywords: pregnancy prevention adolescents stis/stds self-sufficiency
analysis of endoloops, endostaples and endoclips for closing the appendiceal stump during laparoscopic appendectomy

Conditions: Appendicitis Acute; Laparoscopic Surgery

Summary: in this randomized control trial the patients with acute appendicitis will be divided in three groups according to the management of the appendiceal stump(endostapler, endoloop or endoclip). pre-, peri- and postoperative data will be analysed.

acute appendicitis is the most common indication for intraabdominal emergency surgery, and appendectomy is one of the most commonly performed procedures in abdominal surgery. today laparoscopic appendectomy (la) has the status of a ''gold standard'' treatment, and it is accepted as the treatment of choice for acute appendicitis.there are several ways of closing the appendiceal stump.an inadequate closure of the appendiceal stump can lead to morbidity of operated patients. the aim of this study is to assess the efficiency of different closure techniques by focusing on the intraoperative and postoperative complications.the patients will be divided into three groups based on the technique used for appendiceal stump closure, whether it is endoloop, endostapler or endoclip. in the patients included in the study the investigators will analyse demographic data, peroperative laboratory values, clinical data and treatment outcomes. also, the histopathological findings of the specimens and perioperative and postoperative complications will be analysed.

Eligibility criteria:
inclusion criteria: * patients with clinically and radiologically(ultrasound) verified appendicitis exclusion criteria: * patients converted from laparoscopy to open surgery

Keywords: laparoscopic appendectomy endoloop endostapler endoclip
efficacy of remifentanil in preventing emergence agitation

Conditions: Emergence Agitation

Summary: the primary aim of the study was to test the hypothesis that remifentanil administered for analgesia prevents emergence agitation more effectively than fentanyl and n2o in patients undergoing rhinoplasty who received desflurane as an inhaled anesthetic agent. the secondary aim of the study was to compare the demographic data, intraoperative and postoperative hemodynamic data, surgical time and modified aldrete score of patients who received different intraoperative analgesia methods.


Eligibility criteria:
inclusion criteria: the study included patients over the age of 18, planned to undergo rhinoplasty by the plastic and reconstructive surgery department, and american society of anesthesiologist (asa) i-ii. - exclusion criteria: * patients with a known history of allergy to the drugs to be administered in the study, asa iii and above, body mass index (bmi) 35\>kg/m2, younger than 18 years of age, any problems that would prevent general anesthesia in the preoperative evaluation (upper respiratory tract infection, etc.), and those who did not agree to participate in the study were excluded from the study.